Publication date: September 2026 Source: Endocrinology and Metabolism Clinics of North America, Volume 55, Issue 3 Author(s): Rachael Innes, John R. Petrie, Thomas Fremming Dejgaard
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next. // Endocrinology & Metabolism Clinics of North America. – URL: https://www.sciencedirect.com/science/article/pii/S088985292600023X?dgcid=rss_sd_all
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next. Endocrinology & Metabolism Clinics of North America. https://www.sciencedirect.com/science/article/pii/S088985292600023X?dgcid=rss_sd_all
“Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next.” Endocrinology & Metabolism Clinics of North America.
@article{article44628,
title = {Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we’ve Learned and What Comes Next},
journal = {Endocrinology \& Metabolism Clinics of North America},
url = {https://www.sciencedirect.com/science/article/pii/S088985292600023X?dgcid=rss_sd_all}
}